Evidence analysisNovember 17, 2026Health & Science

Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Date of authorisation: 17/07/2015, Revision: 73, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

What is established

Keytruda (active substance pembrolizumab) is an immunotherapy medicine authorized for use in the European Union since July 2015. It is primarily used to treat various advanced or metastatic cancers, including melanoma (skin cancer), non-small cell lung cancer (NSCLC), classical Hodgkin lymphoma, urothelial cancer (bladder/urinary tract), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma, and several others. The medicine works by blocking the PD-1 receptor on immune cells, preventing cancer cells from disabling immune responses and thereby promoting the immune system’s ability to attack tumors.

Keytruda is administered via intravenous infusion or subcutaneous injection at intervals of 3 to 6 weeks, under supervision by a specialist experienced in cancer treatment. It may be prescribed alone or in combination with other cancer therapies, including chemotherapy and targeted agents such as lenvatinib or bevacizumab. Some treatments are conditional on testing tumor markers like PD-L1 expression or microsatellite instability (MSI-H/dMMR) status to select patients more likely to respond.

What the source claims

The European Medicines Agency (EMA) highlights several clinical trials demonstrating Keytruda’s benefits across different cancers:

  • Melanoma: In previously treated patients, Keytruda showed improved progression-free survival and overall survival compared with chemotherapy or ipilimumab. When used after surgery in high-risk patients, Keytruda increased disease-free survival rates compared to placebo.
  • Non-small cell lung cancer (NSCLC): Keytruda improved overall survival compared to chemotherapy in patients previously treated and untreated but strongly expressing PD-L1. When combined with chemotherapy in non-squamous and squamous NSCLC, Keytruda improved survival and delayed disease progression.
  • Adjuvant and neoadjuvant settings: In patients undergoing surgery for melanoma, renal cell carcinoma, and NSCLC, Keytruda reduced the risk of cancer recurrence post-surgery, supporting its use to prevent relapse.

The source reports that Keytruda is also approved for use in children and adolescents for certain cancers such as classical Hodgkin lymphoma and melanoma, extrapolating adult trial data to younger populations based on disease similarity.

What may be missing from the usual framing

The EMA summary focuses primarily on clinical efficacy and safety as demonstrated in trials submitted for regulatory approval. However, it does not discuss in depth:

  • The magnitude and frequency of side effects beyond noting that doses may be delayed or stopped if severe reactions occur.
  • The cost implications of Keytruda treatment, which can be substantial given its nature as a biologic immunotherapy.
  • Comparative effectiveness or cost-benefit analyses versus other emerging cancer therapies or combination regimens beyond the specific trial comparators.
  • Long-term real-world outcomes outside of controlled clinical trials.
  • The patient experience, including quality-of-life measures while on Keytruda.

Competing evidence or uncertainty

The EMA report presents positive trial outcomes but does not extensively address variability in patient responses or cancer subtypes beyond PD-L1 and MSI-H/dMMR biomarker status. Areas of uncertainty include:

  • Which patients benefit most or least based on molecular and genetic tumor profiling beyond PD-L1/MSI status.
  • Resistance mechanisms to PD-1 blockade and how to manage patients whose tumors do not respond or progress after initial response.
  • Potential differences in efficacy and safety profiles when Keytruda is combined with different chemotherapy or targeted agents.
  • Optimal duration of therapy and long-term safety beyond study follow-up periods.
  • Effectiveness in rarer cancers where trial data may be limited.

Additionally, broader independent reviews and meta-analyses are needed to fully establish Keytruda’s place in cancer treatment regimens, alongside evolving standards of care.

Why it matters

Keytruda represents a paradigm shift in oncology by harnessing the immune system to fight cancer, offering hope for durable clinical benefits in cancers that are traditionally hard to treat or have recurred after other treatments. Its approvals across many cancer types underscore its expanding role in modern cancer care. Understanding its evidence base is critical for clinicians, patients, and healthcare systems to make informed decisions about treatment options, balancing efficacy, safety, quality of life, and costs.

Given the significant financial and clinical implications of widespread immunotherapy use, transparent evidence on benefits and risks is important. This enables policymakers and payers to structure access programs and guides ongoing research to optimize patient outcomes.

What to verify next

  • Detailed side effect profiles and management strategies for Keytruda treatment in different cancers and patient groups.
  • Long-term follow-up data reporting on overall survival and quality of life.
  • Real-world studies assessing effectiveness outside controlled trial settings.
  • Comparative effectiveness against emerging immunotherapies or combination therapies.
  • Economic evaluations, including cost-effectiveness and budget impact analyses from public health perspectives.
  • Data from ongoing or future clinical trials expanding indications or refining biomarkers identifying responders.

Readers should consult the original EMA European Public Assessment Report on Keytruda for comprehensive clinical data and regulatory context to inform detailed understanding and clinical decisions.

Source & verification

Primary source: What's new · November 17, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

EudraGMDP database

What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…